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University of Pittsburgh, 2011 
 
 
Cytokines play a major role in bone remodeling in vitro and in animal models, with evidence 
supporting the involvement of inflammatory markers in the pathogenesis of osteoporosis. 
However, less is known about the longitudinal association of inflammatory markers with hip 
fracture, the most devastating consequence of osteoporosis.  The public health significance of hip 
fractures is substantial; the one-year mortality rate after a hip fracture in women is estimated to 
range from 17-22%. Thus, preventing hip fractures is a public health imperative. We tested 
whether high receptor levels of pro-inflammatory cytokines are associated with an increased risk 
of hip fracture in older women. The Women’s Health Initiative Observational Study (WHI-OS) 
is a nested case-control study among 400 cases with physician adjudicated incident hip fractures 
and 400 age, race, and date of blood draw matched controls. Subjects were selected from 39,795 
postmenopausal women without previous hip fractures, not using estrogens or other bone-active 
therapies. Conditional logistic regression was used to estimate the risk ratios for hip fracture. 
Incident hip fractures (median follow-up 7.1 years) were verified by review of radiological, 
magnetic resonance imaging, or operative reports and confirmed by blinded central adjudicators. 
Hip fractures with a pathological cause were excluded. In multivariate models, the risk ratio 
(95% CIs) of hip fracture for subjects with the highest inflammatory markers (quartile 4) 
compared with those with lower inflammatory markers (quartiles 1, 2, and 3) was 1.43 (0.98, 
2.07) for interleukin-6 receptor (IL-6 SR) and 1.41 (0.97, 2.05) for tumor necrosis factor receptor 
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1 (TNF SR1) and 1.57 (1.09-2.25) for tumor necrosis factor receptor 2 (TNF SR2). In subjects 
with all three high inflammatory markers, the risk ratio of fracture was 2.27 (1.04, 4.93) in 
comparison with subjects with 0 or 1 elevated marker(s) (p trend = 0.042). Inflammatory markers 
may be one of the strongest risk factors of hip fracture to date. Future clinical trials should test 
whether interventions to decrease inflammatory marker levels reduces hip fractures.                 
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1.0 INTRODUCTION 
 
Elevated interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) have been shown to be 
associated with an increased risk of adverse outcomes, including type II diabetes(1) mortality(2), 
declines in both physical(3) and cognitive function(4), dementia(5) and cardiovascular disease 
(CVD).(6, 7)  Cytokines also play a major role in bone remodeling, with several in vitro and 
rodent studies showing the involvement of inflammatory markers in the pathogenesis of 
osteoporosis.(8, 9) Pro-inflammatory cytokines (i.e., Il-6 and TNFα) act on mesenchymal stem 
cells and osteoclast precursors to enhance osteoclast mediated bone resorption. In the first 
physiological pathway, IL-6 and TNF-α bind to stromal cells and increase the expression of 
Receptor Activated Nuclear Factor-kB ligand (RANKL), macrophage-colony stimulating factor 
(M-CSF) and decrease osteoprotegerin (OPG) production resulting in increased activation of 
osteoclasts.(10) In the second physiological pathway, estrogen deficiency results in cytokine 
mediated osteoclast activation.(11, 12)   
   The association between pro-inflammatory markers and hip fractures is uncertain. A 
prior prospective study showed that elevated inflammatory markers are a risk factor for incident 
fractures.(13)  However, this prior study included all non-traumatic fractures (N=156) and did 
not have enough power to assess this association for hip fractures (N=39) only. Hip fractures 
contribute the greatest morbidity and mortality among all other osteoporotic fractures.(14) The 
one-year mortality rate after a hip fracture in women is estimated to range from 17-22%.(14)         
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   We conducted a nested case-control study from the Women’s Health Initiative 
Observational Study (WHI-OS) among 400 cases with physician adjudicated  incident hip 
fractures and 400 age, race, and date of blood draw matched controls.  We tested whether high 
receptor levels of pro-inflammatory cytokines are associated with an increased risk of hip 
fracture in older women. We focused specifically on the soluble receptors for inflammatory 
markers as opposed to the markers themselves for the following reasons. In our prior study (13) 
this association was particularly strong for the soluble receptors of TNF. In addition, increases in 
TNF-α and IL-6 are usually transient, whereas elevations of soluble receptors for these cytokines 
appear to be more constant.(15) Prior research suggests that antigens may induce shedding of 
soluble cytokine receptors in an attempt to weaken the inflammatory response. Thus, elevated 
levels of soluble receptors may represent a more prolonged or severe inflammatory state.(16, 17)                   
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2.0 METHODS 
 
2.1 STUDY POPULATION 
 
The WHI-OS is a prospective cohort study that enrolled 93,676 women ages 50-79 years from 
1994-1998 at 40 U S clinical centers.(18) Women were eligible if they were postmenopausal, 
unlikely to move or die within three years, not enrolled in the WHI Clinical Trials and not 
currently participating in any other clinical trial.  The study was approved by Human Subjects 
Review Committees at each participating institution, and all participants provided written 
informed consent. 
 
2.2 FOLLOW-UP AND OUTCOME ASCERTAINMENT 
 
Women were sent questionnaires annually to report the occurrence of any hospitalization and a 
wide variety of outcomes including fractures. Follow-up time ranged from 0.7 - 9.3 years as of 
August, 2004 with a median duration of 7.1 years. At that time, 3.7% of participants  had 
withdrawn or were lost to follow-up and 5.3% had died.  Hip fractures were verified by review 
of radiology reports and confirmed by blinded central adjudicators.(19) Hip fractures with a 
possible or confirmed pathological cause resulting from bone tumors, Paget’s disease, bone and 
joint prosthesis, or surgical manipulation were excluded.  
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2.3 NESTED CASE-CONTROL DESIGN 
 
The present analyses use a nested case-control design within the prospective design of the WHI-
OS. Participants were excluded if they had a prior history of hip fracture at baseline, were 
currently taking hormones or had taken them up to one year prior to enrollment, or at baseline 
were taking androgens, selective estrogen receptor modulators, antiestrogens, or other 
osteoporosis treatments (bisphosphonates, calcitonin). Women without sufficient serum stored or 
with unknown ethnicity were also excluded leaving a final study group of 39,795 eligible 
participants. From the eligible women, a total of 404 incident hip fractures occurred. We 
randomly selected 400 incident hip fractures to comprise the case group. From the remaining 
without hip fractures, one control per case was selected with individual matching by age at 
screening (+/- one year), race/ethnicity, and date of blood draw (+/- 120 days).   
 
2.4 CLINICAL VARIABLES 
 
Current use of personal prescription and over the counter medications was recorded by clinic 
interviewers by direct inspection of containers.  Prescription names were entered into the WHI 
database and assigned drug codes using Medispan software. 
Vitamin and mineral supplements, including usual current supplement doses of 
elemental calcium and Vitamin D preparations, taken at least twice weekly for the prior two 
weeks, were entered directly from information on container labels as described above.  Dietary 
intakes of calcium and Vitamin D were also assessed using a semi-quantitative food frequency 
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questionnaire(20).  Total calcium and Vitamin D intake was defined as  the sum of diet and 
supplements. 
Questionnaires ascertained information on date of birth, race/ethnicity, age  at 
menopause, history of personal fracture after age 55, parental history of hip fracture, diagnosed 
diabetes and if under treatment, current and past smoking amount and duration, self-rated health 
status and lifetime alcohol consumption, corticosteroid use, use of NSAIDs      ≥2 years, and total
number of falls during last follow-up.  Physical activity was classified on the basis of frequency 
and duration of walking and mild, moderate and strenuous recreational activities in the prior 
week. Kilocalories of energy expended in a week was calculated (metabolic equivalent (MET), 
score=kcal hours/week/kg).(21) Physical function was measured using the 10-item Rand-36 
physical function scale.(22) The scale is scored from 0  to 100, with higher scores indicating 
better physical function. We compared women with a score of >90 versus ≤90; this cutoff 
corresponds to the median score. A frailty score was computed and included self-reported muscle 
weakness, impaired walking, exhaustion, low physical activity and unintended weight loss 
between baseline and three years of follow-up.(23)   
Weight was measured on a balance beam scale with the participant dressed in indoor 
clothing without shoes.  Height was measured using a wall-mounted stadiometer.  Body mass 
index (BMI) was calculated as weight (kg)/ height2 (m2).  
 
2.5 LABORATORY METHODS
 
 A 12 hour fasting blood sample was obtained at the baseline visit, processed and stored at - 80º 
C according to strict quality control procedures.(24) Stored serum samples were sent to testing 
laboratories where laboratory personnel were blinded to case-control status for all measurements.  
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Soluble receptors of interleukin 6 (IL-6 SR) and tumor neurosis factor (TNF SR1 and TNF SR2) 
were measured with ELISA (CV% <16%) at the University of Vermont. Sex steroid hormones 
were measured at the Reproductive Endocrine Research Laboratory at USC, a WHI designated 
core laboratory. Estradiol and testosterone concentrations were quantified using sensitive and 
specific RIAs following organic solvent extraction and celite column partition 
chromatography.(25-28) For estradiol, the intra-assay and inter-assay CVs were 7.9% and 8-
12%, respectively and for testosterone, 6% and 10-12%, respectively. Bioavailable hormone 
concentrations were calculated using mass action equations.(29-31) Sex hormone binding 
globulin (SHBG) was measured using a solid phase two site chemiluminescent 
immunoassay.(32) The intra-assay and inter-assay CVs were 4.1-7.7% and 5.8-13%, 
respectively. Serum levels of cystatin-C were measured with the Dade Behring BN-II 
nephelometer and Dade Behring reagents (Ramsey,MN) using a   particle enhanced 
immunonepholometric assay at Medical Research Laboratories International in Highland 
Heights, Kentucky. Serum C-terminal telopeptide of Type 1 collagen (CTx) and aminoterminal 
procollagen extensions propeptide (PINP) were measured by immunoassay (Synarc Inc., Lyon, 
France).  Serum 25-hydroxvitamin D [25(OH)D] was measured by using radioimmunoassay with 
DiaSorin reagents (Diasorin, Stillwater, Minnesota). The sensitivity of the 25(OH)D assay was 
1.5 ng/ml. Interassay CVs were 11.7%, 10.5%, 8.6%, and 12.5% at 5.6, 22.7, 33.0, and 49 ng/ml 
of 25(OH)D.       
      
2.6 STATISTICAL METHODS 
 
Baseline characteristics were compared between hip fracture cases and matched controls, using 
McNemar’s test for categorical variables and paired t-tests for continuous data. The variables IL-
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6 SR, TNF SR1 and TNF SR2 were not normally distributed; therefore all these variables were 
log transformed and subsequently back-transformed to generate geometric means which were 
reported. Geometric means and standard deviations reported are likely to be smaller than normal 
calculations involving untransformed data. The reason for this is that the natural log 
transformation reduces the influence of extreme observations and outliers resulting in 
exponentiated geometric values that inherit the reduced influence of extreme observations.  We 
assigned cytokine soluble receptor concentrations to quartile categories based on the distribution 
within the controls. The complexity and interrelatedness of cytokines involved makes it is 
unlikely that one biomarker would capture all of the risk information. Therefore, a composite 
measure of inflammation which combines the number of soluble cytokine receptors in the 
highest quartile for IL-6 and TNFα was used to determine hip fracture risk. High levels of two or 
more inflammatory markers more likely represent systemic inflammation than a high level of 
just one inflammatory marker.(33, 34) This composite measure was predefined based on our 
prior manuscript.(13)  To further assess the potential for confounding, participant characteristics 
were compared across number of inflammatory markers in the highest quartile. The dose-
response associations for the number of high inflammatory markers and participants 
characteristics were evaluated using Jonckheere Terpstra and Cochrane-Armitage tests of trend, 
and by treating number of high inflammatory markers as  a continuous variable.  
   For multivariable models, the associations were assessed using conditional logistic 
regression models to account for the matched case-control design. The odds ratio was used as an 
approximation of the risk ratio, based on the relative rarity of the outcome incident hip fractures. 
To examine the impact of these biomarkers individually we compared women with the lowest 
cytokine receptor concentrations quartile 1 (Q1) to women with higher concentrations (quartiles 
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2, 3, and 4), and tested for dose-response relationships. Women in the top quartile (Q4) of 
cytokine soluble receptors appeared to be the most at risk for hip fracture; and thus were 
compared to all other women (Q123). Associations were then examined with adjustment for 
BMI, parental history of hip fracture, previous fractures, self-reported health, treated diabetes, 
physical activity smoking, alcohol use, total calcium and vitamin D intake, NSAID use, and 
corticosteroid use. Further multivariable models compared women with 2 or 3 inflammatory 
markers in the highest quartile to women with ≤1 inflammatory marker in the highest quartile. 
To investigate mechanisms by which inflammatory markers might be associated with hip 
fractures, we added the following variables individually to the base model to determine if they 
mediated this association: frailty score, RAND-36 physical function scale, number of falls, sex-
steroid hormones, cystatin-C,  bone turnover, and  serum 25(OH)D. We then adjusted for all 
variables simultaneously (except for frailty, which we hypothesized would be correlated with 
measures of physical function because both rely on the RAND Short Form-36 physical function 
scale). Adding only potential mediators (without confounders) to the crude model (not shown in 
tables to avoid redundancy) strengthened the association among those with 2 inflammatory 
markers in the highest quartile by an estimated 40 percentage points and attenuated the 
association for those with 3 inflammatory markers in the highest quartile by 10 to 20 percentage 
points. The variance inflation factor (VIF) was used to test for multicollinearity in multivariable 
models. VIF values were <2.5 for all covariates indicating that multicollinearity was likely not 
present in this study. 
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3.0 RESULTS 
 
3.1 PARTICIPANT CHARACTERISTICS 
 
The mean age of the subjects was 71 ± 6 .2 years and 95% were white, Table 1.  Hip fracture 
cases had significantly lower BMI, and physical activity. They were more likely to report 
corticosteroid use and current smoking compared to controls. In addition, serum levels of 
25(OH)D, bioavailable estradiol, and bioavailable testosterone were significantly lower among 
cases. Conversely, serum cystatin-C levels were significantly higher among cases. The geometric 
mean inflammatory marker levels of TNF SR1 (p=0.039) and TNF SR2 (p=0.038) were higher 
among cases versus controls.  Also, IL-6 SR was higher for cases compared to controls; however 
this association was not significant (p=0.280).  
       Participant characteristics varied by number of high inflammatory markers, Table 
2. Whites were more likely to have a greater number of high inflammatory markers than other 
ethnicities.  A higher number of high inflammatory markers was positively (p trend<0.05) 
associated with older age, higher BMI, and greater levels of bioavailable estradiol and serum 
cystatin-C.  There was also an inverse association for number of high inflammatory markers with 
higher physical activity, and better self-reported health. SHBG levels decreased as the number of 
high inflammatory markers increased, however this association was not significant (p 
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trend=0.09). Bone resorption marker levels, serum 25(OH)D, and bioavailable testosterone levels 
did not vary by number of high inflammatory markers. 
 
3.2 THE ASSOCIATION OF QUARTILES OF INFLAMMATORY 
MARKERS WITH HIP FRACTURES 
 
There was a lack of a dose-response relationship between increasing quartiles of soluble cytokine 
receptors and hip fracture risk, Table 2. In addition, women in Q4 of cytokine soluble receptor 
concentrations were compared to all other women in the cohort.  In  the unadjusted models, 
women in Q4 of IL-6 SR had 1.53 [95% CI: 1.10 to 2.14] times the risk of incident hip fracture 
compared to women in the lower IL-6 SR quartiles.  This association was slightly attenuated and 
no longer significant in the multivariable model, OR=1.43 [95% CI: 0.98 to 2.07]. The 
association between TNF SR2 and hip fractures remained significant in the multivariable model 
[OR=1.57; 95% CI: 1.09 to 2.25]. There was no association between TNF SR1 and incident hip 
fractures in the multivariable model [OR=1.41; 95% CI: 0.97 to 2.05].   
 
3.3 NUMBER OF HIGH INFLAMMATORY MARKERS AND HIP 
FRACTURE 
 
The risk of incident hip fracture was highest among women with 3 “high” levels (quartile 4) of 
inflammatory markers, Table 3.  In the base analysis,  women  with 2 or 3  high  inflammatory 
markers had 43% [95% CI: -6, 127] and 166% [95% CI: 43, 392] increased risk of incident hip 
fracture compared with those with 0 or  1 level (p trend=0.001), respectively. Adjustment for 
11 
 
potential mediators one at a tim e resulted in sm all attenuations and som e augmentations of the 
association between inflamm atory markers and incident hip f ractures. After adjusting for 
estradiol, the increased risk of  fracture for women with 3 high inflammatory m arkers compared 
to women with 1 or 0 high m arkers went fr om 166% to 209%. The mo st notable attenuation 
(decrease in 40 percentage points) in hip fracture risk occurred after adjusting for cysta tin-C.  
Women with 3 high inf lammatory markers had a 127% [95% CI: 4, 394] in creased risk of hip 
fracture compared to women with 0 or 1 high in flammatory marker in the f inal summary model 
after adjusting for variables in the base m odel and all potential m ediators. There was also a 
positive linear trend (p trend=0.042 ) between number of high inflammatory m arkers and h ip 
fractures in this model.  
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4.0 DISCUSSION 
 
 
In this prospective, nested-case-control study, we found that women in the highest quartile for 
all three of IL-6 SR, TNF SR1 and TNF SR2 had >2 times  the  risk of hip fracture compared to 
women with 1 or 0 inflammatory makers in the highest quartile. This risk is roughly equivalent 
to the risk associated with a one standard deviation decrease in bone mineral density.(35) These 
associations were independent  of  BMI,  self-reported  health status,  physical  activity,  parental   
history of fracture, history of fracture, treated diabetes, calcium and vitamin D intake, NSAID 
and corticosteroid use, frailty physical function, falls, sex hormones, cystatin-C, bone turnover 
markers, and 25(OH)D. These findings extend our previous findings (13) on all clinical fractures 
to hip fractures, the most devastating consequence of osteoporosis. 
   Adjustment for all potential mediators except one augmented the association 
between number of inflammatory marker in the top quartile and incident hip fractures. We 
initially hypothesized that adjusting for bioavailable estradiol would attenuate this association 
because of data showing estrogens oppose the action of cytokines(36). However, in our cohort 
there was a positive association between bioavailable estradiol and number of inflammatory 
markers in  the  highest quartile  independent of  BMI.  Similarly, estradiol  levels  have  been 
shown to be positively correlated with pro inflammatory markers in older women. (37, 38) 
However, contrary to the association of inflammatory makers with hip fracture; bioavailable 
estradiol was negatively associated with hip fractures. Thus, negative confounding(39) occurred 
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after adjustment for bioavailable estradiol in consequence of the directionality of these 
associations.  Conversely, cystatin-C (a marker for poor renal function) was the lone biomarker 
which strongly attenuated the association between inflammatory markers and hip fracture. We 
observed a positive correlation between cystatin-C levels and number of inflammatory markers 
in the highest quartile. Several prospective cohort studies have identified an association between 
inflammatory makers and decline in kidney function.(40-42) Though the biological mechanism 
has not been established, several hypotheses exist. In vivo studies have shown that glomerular 
injury can be induced directly by TNF-α(43, 44), or mediated by immune cells (i.e., monocytes 
and macrophages).(40)   Poor renal function has also been identified  as  a  risk factor for hip 
fractures in older women.(45-47) In our study, cystatin-C concentrations were significantly 
higher in cases versus controls. The directionality of these associations influenced the attenuation 
or positive confounding(39) as a result of adjusting for cystatin-C.  
   There is an increased understanding and recognition of the role of the immune 
system in the development of osteoporosis.(48) Multiple cytokines (pro-inflammatory and anti-
inflammatory) and hormones interact to regulate osteoblast and osteoclast differentiation and 
activity. The balance in these systems plays an important role in the regulation of osteoblasts and 
osteoclasts. In addition, several longitudinal studies among older women have found an 
association between high levels of inflammatory makers and increased bone loss.(49-52) 
However, in our analyses of the Health ABC cohort, the association between inflammation and 
fractures was independent of BMD.(13) 
   TNFα stimulates osteoclast bone resorption in vitro and in vivo, (53, 54) possibly 
increasing bone resorption through the differentiation of osteoclast precursors. This can be 
accomplished indirectly through suppression of OPG expression and stimulation of RANK in 
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cells.(10) TNFα has also been shown to activate osteoclast precursors directly by acting 
synergistically with RANKL. This direct mechanism occurs as a result of estrogen deficiency 
leading to a marked increase of TNFα.(11)  The increased risk  of  hip  fracture  was greater for 
those in the highest quartile for TNF SR2 (57%) and TNF SR1 (41%) compared to other 
participants. Our previous study found similar risks between soluble receptors for TNFα and 
incident fractures.(32) This suggests that the role of these biological markers in fracture etiology 
may be similar for hip and other types of fractures. 
   IL-6 may influence bone remodeling and osteoporosis.(48) IL-6 is stimulated in 
response to PTH and other cytokines including TNFα.(55)  IL-6 SR may enhance biological 
activity of IL-6. In cell culture, IL-6 only stimulated osteoclastogenesis, in the presence of IL-6 
SR.(56) Also, in transgenic mice, IL-6 SR may bind to IL-6 and increase its biological activity.  
In our study, the association between serum IL-6 SR and hip fractures was considerable, but not 
significant. The risk of hip fracture was 43% more likely among participants in the highest IL-6 
SR quartile compared to other subjects, but it was not statistically significant.   
   Our study has a number of strengths. We examined multiple markers of 
inflammation in relation to incident hip fractures, the most serious consequence of osteoporosis. 
We also adjusted for many potential confounders, eliminated hormone users from analysis, and 
explored several mechanisms of potential mediation underlying this association in order to focus 
more carefully on this group. There were several limitations in our study.  BMD was only 
measured in 3 WHI clinics, thus we were unable to account for it in our analysis. However, the 
association of inflammatory markers with incident fractures was independent of BMD in our 
previous analyses.(13) Also, hip fractures are a rare outcome in our study population affecting 
approximately 1.01% of women with an annual risk of about 0.14%.  This may reflect their 
15 
 
relatively  young  age (age 50-79 years)  at enrollment. Among women in a top cytokine soluble 
receptor quartile, there  was an estimated  50% increase in  risk, compared to all  other women. 
Therefore, the  absolute  risk  may  have  only  increased from  approximately 0.14% per year to 
around 0.22%  for  women  in  a  top  inflammatory  marker  quartile. Our results are  primarily 
generalizable to older Caucasian women. We measured cytokine soluble receptor concentrations 
in the serum; however these  levels may differ in the bone  microenvironment  and  over  time. 
Serum assays may not reflect local cytokine  soluble  receptor  levels. Several covariates (i.e., 
physical activity and dietary and supplem entary intake of calcium ) were m easured using self-
report; therefore misclassification as a consequence of  recall  bias is possible. Finally, residual 
confounding due to unmeasured factors is a component of all observational studies. In summary, 
elevated levels of inflammatory markers for all 3 cytokine soluble receptors were associated with 
an increased risk of hip fractures in older women.  
Future clinical  trials  should  test  whether interventions  to  decrease  inflammatory 
marker levels reduces hip fractures. 
16 
 
 
 
 
5.0 TABLES 
 
 
 
Table 1. Baseline characteristics among 400 matched hip fracture cases and controls 
 Controls 
N (%) 
Mean ± Std 
Hip Fractures 
N (%) 
Mean ± Std 
P-value+ 
Ethnicity   >0.99 
  White 380 (95.0) 380 (95.0)  
  Black 10 (2.5) 10 (2.5)  
  Hispanic 2 (0.5) 2 (0.5)  
  American Indian 3 (0.8) 3 (0.8)  
  Asian/Pacific Islander 5 (1.3) 5 (1.3)  
Age at baseline >70 years 132 (33.0) 132 (33.0) >0.99 
Body mass index (BMI), kg/m2   <0.01 
  <25 144 (36.1) 193 (48.6)  
  25-30 150 (37.6) 127 (32.0)  
  ≥30 105 (26.3) 77 (19.4)  
Hormone therapy usage status   0.80 
  Never used 302 (75.5) 305 (76.3)  
  Past user 98 (24.5) 95 (23.8)  
Corticosteroid use 4 (1.0) 16 (4.0) 0.01 
NSAID use ≥2 years 21.7 20.7 0.73 
RAND 36 – Physical functioning >90 117 (30.1) 84 (21.8) 0.01 
Frailty 16.5 22.3 0.04 
General health status, fair/poor 42 (10.6) 61 (15.3) 0.05 
Treated diabetes 4.8 6.0 0.43 
17 
 
Alcohol    0.61 
Non drinker 70 (17.6) 58 (14.6)  
Past drinker 80 (20.2) 89 (22.4)  
<1 drink per day 205 (51.6) 212 (53.3)  
≥1 drinks per day 42 (10.6) 39 (9.8)  
Smoking   <0.01 
Never smoked 215 (54.3) 214 (54.3)  
Past smoker 171 (43.2) 144 (36.6)  
Current smoker 10 (2.5) 36 (9.1)  
History of fracture age ≥55 years 82 (20.5) 96 (24.0) 0.24 
Parental history of hip fracture 64 (16.0) 80 (20.0) 0.14 
Total expend phys act, MET – hrs/week 13.9 ± 15.3 10.7 ± 12.7 <0.01 
Total number of falls at follow-up 2.8 ± 3.2 2.4 ± 2.7 0.09 
Total vitamin D intake, IU/day  373 ± 276 383.0 ± 396 0.71 
Serum 25(OH)D, ng/ml 23.9 ±  7.2 22.4 ± 8.1 0.01 
Total calcium Intake , mg/day  1167 ± 684 1072 ± 694 0.05 
TNF SR1, pg/ml* 1595.1 ± 1.2 1702.2 ± 1.3 0.04 
TNF SR2, pg/ml* 2489.2 ± 1.3 2583.2 ± 1.3 0.04 
IL-6 SR, pg/ml* 37384.1 ± 1.5 38561.1 ± 1.5 0.28 
Bioavailable estradiol, pg/ml  7.5 ± 4.5 6.6 ± 4.3 <0.01 
Bioavailable testosterone, pg/ml 12.6 ± 7.0 10.9 ± 6.3 <0.01 
SHBG, µg/dl 1.6 ± 0.8 1.8 ± 0.9 <0.01 
Cystatin-C, mg/L 1.06 ± 0.2 1.10 ± 0.3 0.02 
PINP, ng/ml  49.6  ± 23.7 51.0 ± 23.0 0.42 
CTx, ng/ml 0.41 ± 0.19 0.45 ± 0.22 0.02 
*Geometric means and standard deviations 
+P-values from McNemar’s test for categorical data and paired t-tests for continuous data 
 
 
 
 
Table 1 Continued  
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Table 2: Baseline characteristics by number of high inflammatory markers in the control group. 
 0  
(N=211) 
1  
(N=101) 
2  
(N=63) 
3  
(N=24) 
P trend 
 N (%) 
Mean ± Std 
N (%) 
Mean ± Std 
N (%) 
Mean ± Std 
N (%) 
Mean ± Std 
 
Ethnicity     0.58 
  Whites 196 (92.9) 98 (97.0) 61 (96.8) 24 (100)  
  Blacks 7 (3.3) 1 (0.98) 2 (3.2) 0 (0.0)  
  Hispanic/American Indian/Asian 8 (3.8) 2 (1.96) 0 (0.0) 0 (0.0)  
Age at baseline >70 years  129 (61.1) 68 (67.3) 50 (79.4) 20 (80.3) <0.01 
Body mass index (BMI), kg/m2      
  <25 87 (41.4) 36 (35.6) 14 (22.2) 6 (25.0) <0.01 
  25-30 80 (38.1) 38 (37.6) 24 (38.1) 8 (33.3)  
  ≥30 43 (20.5) 27 (26.7) 25 (39.7) 10 (41.7)  
Hormone therapy usage status     0.46 
  Never used  165 (78.2) 69 (68.3) 46 (73.0) 21 (87.5)  
  Past user 46 (21.8) 32 (31.7) 17 (27.0) 3 (12.5)  
Corticosteroid use  2 (1.0) 0 (0.0) 2 (3.2) 0 (0.0) 0.59 
NSAID use ≥2 years 43 (20.4) 22 (21.8) 18 (28.6) 4 (16.7) 0.44 
RAND 36– Physical functioning >90 70 (34.3) 30 (30.0) 12 (19.7) 4 (17.4) 0.02 
Frailty 30 (14.2) 16 (15.8) 12 (19.1) 8 (33.3) 0.07 
General health status, fair/poor 17 (8.3) 13 (13.0) 8 (12.9) 4 (17.4) <0.01 
Treated diabetes 6 (2.8) 5 (5.0) 5 (7.9) 3 (12.5) 0.02 
Alcohol     0.09 
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  Non drinker 34 (16.2) 13 (12.9) 17 (27.9) 6 (25.0)  
  Past drinker 44 (21.0) 17 (16.8) 15 (24.6) 4 (16.7)  
  <1 drink per day 107 (51.0) 56 (55.5) 28 (45.9) 13 (54.2)  
  ≥1 drinks per day 25 (11.9) 15 (14.8) 1 (1.6) 1(4.2)  
Smoking     0.51 
  Never smoked 112 (53.9) 50 (49.5) 41 (66.1) 11 (45.8)  
  Past smoker 88 (42.3) 50 (49.5) 21 (33.9) 12 (50.0)  
  Current smoker 8 (3.9) 1 (1.0) 0 (0) 1 (4.2)  
History of fracture age ≥55 years 44 (20.9) 19 (18.8) 12 (19.1) 7 (29.2) 0.73 
Parental history of  hip 31 (14.7) 18 (17.8) 13 (20.6) 2 (8.3) 0.76 
Total expend phys act, MET–hrs/week 15.2 ± 16.2 13.7 ± 13.3 11.5 ± 16.2 8.5 ± 10.7 0.02 
Total number of falls at follow-up 2.8 ± 3.5 3.0 ± 3.6 2.7 ± 3.6 2.6± 3.5 0.83 
Total vitamin D intake, IU/day 357.2 ± 278.4 398.0 ± 268.4 426.4 ± 279.2 263.6 ± 224 0.78 
25(OH)D, ng/ml 23.8 ± 6.9 24.2 ± 6.3 24.4 ± 7.5 21.3 ± 8.2 0.51 
Total calcium intake, mg/day 1166.6 ± 718.4 1196.6 ± 666.7 1216.4 ± 619.6 925.1 ± 599.6 0.51 
Bioavailable estradiol, pg/ml 7.1 ± 4.3 6.8 ± 3.4 9.1 ± 5.2 11.1 ± 6.7 <0.01 
Bioavailable testosterone , ng/dl 12.4 ± 7.0 13.0 ± 7.8 11.8 ± 4.9 14.6 ± 7.5 0.52 
SHBG, µg/dl 1.6 ± 0.7 1.6 ± 0.9 1.5 ± 0.7 1.4 ± 0.6 0.09 
Cystatin-C, mg/L 0.97 ± 0.14 1.03 ± 0.17 1.29 ± 0.36 1.34 ± 0.30 <0.01 
PINP, ng/ml 49.1 ± 25.9 48.4 ± 17.3 53.1 ± 25.8 49.4 ± 21.1 0.49 
CTx, ng/ml 0.41 ± 0.19 0.40 ± 0.15 0.44 ± 0.23 0.42 ± 0.20 0.47 
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Table 3: WHI: Risk ratios (95% CI’s) of hip fracture+ according to quartiles of cytokine soluble receptor concentrations among the 
controls   
 Q1 Q2 Q3 Q4  P-trend Q4 vs. Q123* 
IL-6 SR        
  Unadjusted (N pairs=399) 1.00 0.74 (0.48, 1.15) 0.75 (0.50, 1.11) 1.26 (0.84, 1.89) 0.282 1.53 (1.10, 2.14) 
  MV model¶ (N pairs=363) 1.00 0.60 (0.36,1.01) 0.64 (0.40, 1.02) 1.06 (0.65, 1.71) 0.760 1.43 (0.98, 2.07) 
TNF SR1        
  Unadjusted (N pairs=396) 1.00 0.94 (0.54, 1.35) 1.08 (0.72, 1.61) 1.31 (0.88, 1.94) 0.088 1.33 (0.98, 2.09) 
  MV model¶ (N pairs=360) 1.00 1.07 (0.67, 1.73) 1.11 (0.68, 1.79) 1.49 (0.90, 2.47) 0.125 1.41 (0.97, 2.05) 
TNF SR2       
  Unadjusted (N pairs=398) 1.00 1.09 (0.73, 1.64) 1.00 (0.66, 1.51) 1.57 (1.06, 2.33) 0.033 1.53 (1.12, 2.09) 
  MV model¶ (N pairs=362) 1.00 1.09 (0.68, 1.73) 0.96 (0.59, 1.55) 1.57 (0.97, 2.53) 0.105 1.57 (1.09, 2.25) 
+Hip fractures and controls selection matched on age, ethnicity and blood draw date. 
¶Multivariable adjustment includes BMI, self-reported health, physical activity, parental history of hip fracture, history of fracture, smoking, alcohol use, NSAID 
use, treated diabetes, corticosteroid use, and total calcium and vitamin D intake. 
*Reference group (quartiles 1, 2, and 3 combined) 
IL-6 SR quartile cut points (pg/ml) are 31007.98, 39222.27 and ≥47713.73  
TNF SR1 quartile cut points (pg/ml) are 1373.34, 1566.66, and ≥1842.70  
TNF SR2 quartile cut points (pg/ml) are 2113.50, 2489.66, and ≥2848.40  
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Table 4. Risk ratios (95% CIs) of hip fracture, according to number of high inflammatory markers 
 0,1 
(N=588) 
2 
(N=131) 
3 
(N=75) 
P trend 
Crude analysis (N pairs=394) 1.00 (ref) 1.25 (0.84 – 1.84) 2.42 (1.43 –  4.09) 0.001 
P-value  0.267 0.001  
Base analysis†  (N pairs= 358) 1.00 (ref) 1.43 (0.94 – 2.27) 2.66 (1.43 –  4.92) 0.001 
P-value  0.136 0.002  
Base analysis† + frailty score (N pairs=358) 1.00 (ref) 1.45 (0.91 – 2.31) 2.59 (1.40 – 4.81) 0.002 
P-value   0.070 0.002  
Base analysis† + RAND 36 Physical Functioning (N pairs = 344) 1.00 (ref) 1.39 (0.88 – 2.18) 2.70 (1.47 – 4.91) <0.001 
P-value  0.160 0.001  
Base analysis† + total number of falls at follow-up (N pairs = 333) 1.00 (ref) 1.45 (0.90 – 2.34) 2.81 (1.47 – 5.39)  0.002 
P-value  0.131 0.002  
Base analysis† + bioavailable estradiol (N pairs=348) 1.00 (ref) 1.55 (0.96 – 2.50) 3.09 (1.63 – 5.87) <0.001 
P-value  0.075  0.001  
Base analysis + bioavailable testosterone (N pairs=355) 1.00 (ref) 1.39 (0.87 – 2.23) 2.92 (1.53 – 5.55) <0.001 
P-value  0.085 <0.001  
Base analysis† + SHBG (N pairs=356) 1.00 (ref) 1.40 (0.87 – 2.24)  2.67 (1.43 –  4.99) 0.002 
P-value  0.166 0.002  
Base analysis† + cystatin-C  (N pairs=353) 1.00 (ref) 1.32 (0.78–2.23) 2.26 (1.14 –4.48)  0.021 
P-value  0.299 0.020  
Base analysis† + PINP  (N pairs=345) 1.00 (ref) 1.49 (0.92–2.41) 2.81 (1.49–5.31)  0.001 
P-value  0.108 0.001  
Base analysis† + CTx (N pairs=348) 1.00 (ref) 1.42 (0.88 – 2.30) 2.50 (1.34 – 4.66) 0.003 
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P-value  0.155 0.004  
Base analysis† + 25(OH)D (N pairs=357) 1.00 (ref)   1.42 (0.89 – 2.28) 2.65 (1.43 – 4.92) <0.001 
P-value  0.146 0.002  
Summary multivariate model§  (N pairs =301)                     1.00 (ref) 1.33 (0.74-2.39) 2.27 (1.04-4.93)  0.042 
P-value  0.345 0.039  
 N indicates number of case-control pairs included in the analysis.  
†Base analysis was matched on age, ethnicity, blood draw date, controlled for BMI, self-reported health, physical activity, parental history of fracture, history 
 of fracture, smoking, alcohol use, NSAID use, treated diabetes, corticosteroid use, and total calcium and vitamin D intake.  
 §Controlled for base analysis, physical function, total number of falls, bioavailable estradiol and testosterone, SHBG, cystatin-C, PINP, CTx, and 25(OH)D.  
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